(Q51820508)

13 April 2018

title

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. (English)

1 reference

13 April 2018

cervical intraepithelial neoplasia

main subject

1 reference

García-Hernández E

1

1 reference

13 April 2018

González-Sánchez JL

2

1 reference

13 April 2018

Andrade-Manzano A

3

1 reference

13 April 2018

Contreras ML

4

1 reference

13 April 2018

Padilla S

5

1 reference

13 April 2018

Guzmán CC

6

1 reference

13 April 2018

Jiménez R

7

1 reference

13 April 2018

Reyes L

8

1 reference

13 April 2018

Morosoli G

9

1 reference

13 April 2018

Verde ML

10

1 reference

13 April 2018

Rosales R

11

1 reference

13 April 2018

publication date

1 June 2006

1 reference

13 April 2018

published in

Cancer Gene Therapy

1 reference

13 April 2018

volume

13

1 reference

13 April 2018

issue

6

1 reference

13 April 2018

page(s)

592-597

1 reference

13 April 2018

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700937

exact match

0 references

cites work

Human papillomavirus vaccines and prevention of cervical cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700937

A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700937

Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700937

Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700937

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700937

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700937

MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700937

Development of a DNA-MVA/HIVA vaccine for Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700937

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700937

Estimates of the worldwide frequency of sixteen major cancers in 1980

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700937

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.CGT.7700937

1 reference

13 April 2018

1 reference

13 April 2018